Evidence map›Paper›PMID 29780111›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma.

Shigeo Godo, Yoshitaro Yoshida, Naoki Kawamorita, Koji Mitsuzuka, Yu Kawazoe, Motoo Fujita, Daisuke Kudo, Ryosuke Nomura, Hiroaki Shimokawa, Shigeki Kushimoto

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shigeo GodoDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan.
Yoshitaro YoshidaDepartment of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan.
Naoki KawamoritaDepartment of Urology, Tohoku University Graduate School of Medicine, Japan.
Koji MitsuzukaDepartment of Urology, Tohoku University Graduate School of Medicine, Japan.
Yu KawazoeDepartment of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan.
Motoo FujitaDepartment of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan.
Daisuke KudoDepartment of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan.
Ryosuke NomuraDepartment of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan.
Hiroaki ShimokawaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan.
Shigeki KushimotoDepartment of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan.
Tohoku University · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia. An abundance of caution for unusual and unpredictable toxicities is warranted when using axitinib.

Indexed as

Aged, 80 and overAntineoplastic AgentsAxitinibCarcinoma, Renal CellFemaleHumansHyperkalemiaKidney NeoplasmsTreatment OutcomeAntineoplastic AgentsAxitinibadverse eventaxitinibhyperkalemiarenal cell carcinoma

Identifiers

PMID29780111
PMCPMC6207819
OpenAlexW2804274162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.